Results 71 to 80 of about 14,850 (194)

Dapagliflozin Improves Angiogenesis after Hindlimb Ischemia through the PI3K-Akt-eNOS Pathway

Biomolecules
Recently, the vascular protective effect of anti-diabetic agents has been receiving much attention. Sodium glucose cotransporter 2 (SGLT2) inhibitors had demonstrated reductions in cardiovascular (CV) events.
Li Han, Guoxin Ye, Wenjing Su, Yuankang Zhu, Wenqi Wu, Liangshi Hao, Jing Gao, Zhen Li, Fang Liu, Junli Duan   +9 more
doaj   +1 more source

NetMetaEasy: enabling rapid and user‐friendly network meta‐analysis (NMA) for comparative effectiveness research

British Journal of Pharmacology, EarlyView.
Background and Purpose Network meta‐analysis (NMA) enables the simultaneous comparison of multiple treatments by combining direct and indirect evidence across a network of studies. While its application is rapidly expanding in pharmacological research and clinical guideline development, performing NMA typically requires advanced statistical knowledge ...
János Tibor Fekete, András Komócsi, Balázs Győrffy   +2 more
wiley   +1 more source

Emerging Role of Ferroptosis in Diabetes and Associated Complications: When Metabolic Dysregulation Meets Cell Death

Cell Proliferation, EarlyView.
This study identifies ferroptosis as a key driver of diabetes and its complications via iron metabolism and lipid peroxidation, elucidates organelle interactions underlying cell vulnerability, and provides insights for targeted therapies against metabolic disorders.
Zheng Wang, Ying Zhang, Yue Xu, Mengyuan Yang, Yuan Wei, Yuan Li, Tongyue Yang, Xu Wang, Chaona Yang, Qi Feng, Guolan Xing   +10 more
wiley   +1 more source

Sodium‐Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction‐Associated Steatohepatitis [PDF]

J Diabetes
MASH denotes metabolic dysfunction‐associated steatohepatitis. MASH improvement was defined as a decrease in the non‐alcoholic fatty liver disease activity score (NAS) of ≥ 2 points or NAS ≤ 3 at week 48 after treatment, with no worsening of fibrosis (i.e., no increase in fibrosis stage). MASH resolution was defined as a hepatocellular ballooning score
Lin J, Huang Y, Xu B, Huang C, Teng F, Yuan Y, Zhang J, Zhang H.   +7 more
europepmc   +2 more sources

Diabetes management in people undergoing metabolic‐bariatric surgery: A guideline from the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP) Group

Diabetic Medicine, EarlyView.
Abstract The global prevalence of obesity and diabetes continues to rise, with metabolic‐bariatric surgery recognised as an effective intervention for obesity and type 2 diabetes, offering potential for type 2 diabetes remission and improved glycaemic control. This guideline, developed by the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP)
Jeffrey W. Stephens, Ketan Dhatariya, Andrew J. Beamish, Dimitri J. Pournaras, Alexander D. Miras, Nader Raafat, Georgia Noble‐Bell, Rachel Cadwallader Buckland, Omar G. Mustafa   +8 more
wiley   +1 more source

Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley   +1 more source

Response to the Nephrological perspectives on the underutilization of SGLT2i in heart failure and chronic kidney disease

ESC Heart Failure, Volume 12, Issue 2, Page 1492-1493, April 2025.
Umut Kocabas
wiley   +1 more source

Metabolic liver disease: A summary of major guidelines and identifying opportunities to improve future guidelines

Diabetes, Obesity and Metabolism, EarlyView.
Abstract The clinical management of metabolic dysfunction‐associated steatotic liver disease (MASLD) and metabolic dysfunction‐associated steatohepatitis (MASH) is undergoing rapid evolution, driven by advances in noninvasive diagnostics and the recent approval of liver‐directed therapies.
Fernando Bril
wiley   +1 more source

Nephrological perspectives on the underutilization of SGLT2is in heart failure and chronic kidney disease

ESC Heart Failure, Volume 12, Issue 2, Page 1490-1491, April 2025.
Özant Helvacı, Ömer Faruk Akçay, Emre Yaşar, Ülver Derici, Galip Güz   +4 more
wiley   +1 more source

Sodium‐glucose co‐transporter 2 inhibitors and obesity‐associated cancers in people with type 2 diabetes: A real‐world observational study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To investigate the association between sodium‐glucose co‐transporter 2 inhibitors (SGLT‐2i) and obesity‐associated cancers (OAC) in individuals with type 2 diabetes (T2D). Materials and Methods This retrospective cohort study used data from the TriNetX US Collaborative Network.
Testimony Ipaye, Jonathan Goldney, Thomas Yates, Francesco Zaccardi, Kamlesh Khunti, Elina Akalestou, Melanie J. Davies, Karen Brown, Dimitris Papamargaritis   +8 more
wiley   +1 more source